Brokerages Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Target Price at $28.63

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have been given an average rating of “Reduce” by the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $28.63.

A number of brokerages have weighed in on IART. Citigroup lowered their price target on Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating on the stock in a research report on Thursday, August 22nd. BTIG Research decreased their target price on Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating on the stock in a report on Wednesday, August 28th. Truist Financial cut their price target on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating for the company in a report on Tuesday, July 30th. JMP Securities reduced their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Finally, Morgan Stanley increased their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th.

Institutional Investors Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Capital Research Global Investors grew its stake in shares of Integra LifeSciences by 37.7% in the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after acquiring an additional 1,621,655 shares in the last quarter. Madison Avenue Partners LP increased its holdings in shares of Integra LifeSciences by 8.0% during the fourth quarter. Madison Avenue Partners LP now owns 1,042,156 shares of the life sciences company’s stock worth $45,386,000 after purchasing an additional 77,489 shares during the period. Jane Street Group LLC increased its holdings in shares of Integra LifeSciences by 181.1% during the first quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company’s stock worth $4,427,000 after purchasing an additional 80,463 shares during the period. Leeward Investments LLC MA boosted its stake in shares of Integra LifeSciences by 17.8% in the first quarter. Leeward Investments LLC MA now owns 452,438 shares of the life sciences company’s stock valued at $16,039,000 after buying an additional 68,247 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Integra LifeSciences by 4.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock worth $70,340,000 after buying an additional 63,323 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 2.3 %

NASDAQ IART opened at $17.87 on Monday. Integra LifeSciences has a 12 month low of $16.96 and a 12 month high of $45.42. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The stock has a 50 day moving average of $21.33 and a 200-day moving average of $27.14. The company has a market cap of $1.41 billion, a PE ratio of 35.74, a PEG ratio of 0.60 and a beta of 1.10.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. The firm had revenue of $418.20 million during the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.71 earnings per share. On average, equities research analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.